- Home
- MGIC vs CMMB Comparison
MGIC vs CMMB Comparison
Compare MGIC & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGIC
- CMMB
- Stock Information
- Founded
- MGIC 1983
- CMMB 2004
- Country
- MGIC Israel
- CMMB Israel
- Employees
- MGIC N/A
- CMMB N/A
- Industry
- MGIC Computer Software: Prepackaged Software
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- MGIC Technology
- CMMB Health Care
- Exchange
- MGIC Nasdaq
- CMMB Nasdaq
- Market Cap
- MGIC 788.0M
- CMMB 23.0M
- IPO Year
- MGIC 1991
- CMMB N/A
- Fundamental
- Price
- MGIC $20.70
- CMMB $1.21
- Analyst Decision
- MGIC Buy
- CMMB Strong Buy
- Analyst Count
- MGIC 2
- CMMB 2
- Target Price
- MGIC $16.00
- CMMB $8.50
- AVG Volume (30 Days)
- MGIC 67.6K
- CMMB 186.3K
- Earning Date
- MGIC 08-13-2025
- CMMB 08-20-2025
- Dividend Yield
- MGIC 2.72%
- CMMB N/A
- EPS Growth
- MGIC 1.33
- CMMB N/A
- EPS
- MGIC 0.76
- CMMB N/A
- Revenue
- MGIC $569,136,000.00
- CMMB N/A
- Revenue This Year
- MGIC $7.53
- CMMB N/A
- Revenue Next Year
- MGIC $8.96
- CMMB N/A
- P/E Ratio
- MGIC $27.24
- CMMB N/A
- Revenue Growth
- MGIC 6.37
- CMMB N/A
- 52 Week Low
- MGIC $9.64
- CMMB $0.87
- 52 Week High
- MGIC $20.83
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- MGIC 85.69
- CMMB 37.38
- Support Level
- MGIC $17.93
- CMMB $1.17
- Resistance Level
- MGIC $18.26
- CMMB $1.22
- Average True Range (ATR)
- MGIC 0.44
- CMMB 0.06
- MACD
- MGIC 0.33
- CMMB -0.01
- Stochastic Oscillator
- MGIC 97.76
- CMMB 37.50
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.